📊 PRO: This Week in Visuals
LLY MRK AMGN NVO PFE ANET SNDK TEAM DDOG NET DOCN HUBS FIG KVYO TWLO PAYC AXON MELI DASH CPNG XYZ FI CRCL TOST CART ETSY Z BKNG ABNB MAR EXPE APP TTD SPOT PINS SNAP MTCH DUOL NYT PTON SONY TTWO
Welcome to the Saturday PRO edition of How They Make Money.
Over 300,000 subscribers turn to us for business and investment insights.
In case you missed it:
Premium members get:
📊 Monthly reports: 200+ companies visualized.
📩 Tuesday articles: Exclusive deep dives and insights.
📚 Access to our archive: Hundreds of business breakdowns.
PRO members get everything PLUS:
📩 Saturday PRO reports: Timely insights on the latest earnings.
Today at a glance:
💊 Eli Lilly: Volume Crushes Price
🦠 Merck: The Bridge Broadens
🧬 Amgen: Growth Outruns the Cliff
🇩🇰 Novo Nordisk: Pill Holds Up
💉 Pfizer: Pipeline Questions
🌐 Arista Networks: Supply Catches Up
💾 Sandisk: AI Eats NAND
☁️ Cloudflare: Agentic Acceleration
🌊 DigitalOcean: AI Accelerates
🐶 Datadog: AI Concentration Bites
☁️ Atlassian: Enterprise Breakout
📢 HubSpot: Pricing Pivot Bites
🎨 Figma: AI Credits Scale
🏴 Klaviyo: Agents Gain Traction
💬 Twilio: Expansion Returns
💻 Paycom: Margins Do the Work
⚡️ Axon: Dedrone Breaks Out
🤝 MercadoLibre: Brazil Bet Pays Off
🥡 DoorDash: DashPass Takes Over
🇰🇷 Coupang: Customers Return
🥕 Instacart: Customers Come Back
📦 Etsy: Back to Etsy
🍞 Toast: Locations Reaccelerate
🔲 Block: Square Catches Up
💳 Fiserv: Reset Gets Deeper
🪙 Circle: Arc Hits the P&L
🏠 Zillow: Growth Without Traffic
🏝️ Booking: Travel Holds Up
🛖 Airbnb: Hotels Check In
🏨 Marriott: US Momentum Holds
✈️ Expedia: Consumer Catches Up
📱 AppLovin: Model Timing Miss
📺 The Trade Desk: Growth Stalls
📌 Pinterest: Growth Speed Bump
👻 Snap: Reset Starts Working
🎧 Spotify: 300 Million Paid
🔥 Match Group: Tinder Stabilizes
🦉 Duolingo: Streak Revival
🗞️ NYT: Subscriber Growth Slows
🚲 Peloton: Profit Without Growth
🎮 Sony: Beyond PlayStation
🎮 Take-Two: GTA VI Preorders Explode
📺 Fox: World Cup Windfall
🏈 Flutter: FanDuel Needs a Reset
👑 DraftKings: Predictions Get Expensive
🍟 McDonald’s: Value Misfires
🍔 RBI: Burger King Breaks Out
🌭 Kraft Heinz: Green Shoots
⚡️ Celsius: Alani Carries the Portfolio
1. 💊 Eli Lilly: Volume Crushes Price
Lilly’s Q2 revenue jumped 48% Y/Y to $23.0 billion ($2.3 billion beat), while adjusted EPS was $8.38 ($1.80 beat). Revenue growth came from a 60% increase in volume, more than offsetting a 13% decline in realized prices.
Mounjaro surged 91% to $9.9 billion and Zepbound grew 46% to $4.9 billion, bringing combined GLP-1 revenue to nearly $15 billion. International Mounjaro sales more than doubled to $5.2 billion as Lilly expands access globally, despite significant price reductions including China reimbursement.
Foundayo, Lilly’s newly launched oral GLP-1 obesity pill, generated $98 million in its first quarter on the market. The next-generation pipeline also advanced materially: retatrutide (triple-hormone obesity injection targeting GLP-1, GIP, and glucagon) delivered positive results in three additional Phase 3 obesity trials. Lilly plans to file with the FDA in Q1 2027.
Lilly raised FY26 revenue guidance to $85–$87 billion, a $2.5 billion midpoint increase. Underlying EPS guidance was also raised by $2.78 at the midpoint, but $3.03 of acquisition-related R&D charges offset that improvement, leaving reported guidance at $35.50–$36.50.
Bottom Line: The GLP-1 story remains a volume machine. Lilly is deliberately giving up price to expand access, and demand is more than compensating. Foundayo adds a new format today, while retatrutide increasingly looks like the next major leg of the obesity franchise.